<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566147</url>
  </required_header>
  <id_info>
    <org_study_id>TR-RPE-RP/LCA</org_study_id>
    <nct_id>NCT03566147</nct_id>
  </id_info>
  <brief_title>Treatment of RP and LCA by Primary RPE Transplantation</brief_title>
  <official_title>Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyecure Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eyecure Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment
      Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber
      Congenital Amaurosis (LCA) Patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>best-corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leber Congenital Amaurosis, Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300,000 HuRPE cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500,000 HuRPE cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000,000 HuRPE cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human primary Retinal Pigment Epithelial (HuRPE) cells</intervention_name>
    <description>HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.</description>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_label>low dose group</arm_group_label>
    <arm_group_label>middle dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of RP or LCA;

          2. Experimental eye with best-corrected visual acuity (BCVA) of no more than 35 letters
             or visual field of less than 10 degree;

          3. Patient understand and sign the consent form.

        Exclusion Criteria:

          1. Blood routine examination is abnormal (hemoglobin&lt;10gm/dL; blood platelet
             count&lt;100k/mm³; neutrophil count&lt;1000/mm³)

          2. Blood biochemistry is abnormal (ALT／AST&gt;1.5; creatinine&gt;1.3mg/dL)

          3. Experimental eye has optic nerve atrophy caused by glaucoma

          4. Experimental eye has retinal detachment, or has received retinal detachment surgery.

          5. Patients with uveitis and other endophthalmitis

          6. Patients with other ocular disease affecting vision.

          7. Patients have participated in clinical study of ocular or systemic drug use in recent
             6 months.

          8. Patients with medical history of malignant cancer (except resected basal cell
             carcinoma and squamous-cell carcinoma).

          9. Patients with medical history of myocardial infarction

         10. Patient with diabetes

         11. Patient with Parkinson disease or Alzheimer's disease

         12. Patients are under the treatment of immunosuppressive agent (except intermittent,
             low-dose corticosteroid treatment).

         13. Patients with other medical conditions that restricts the compliance and safety of
             patients, or affects experimental results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ningli Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingxue Zhang, Dr</last_name>
    <phone>86-18610772626</phone>
    <email>jingxuezh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingxue Zhang, Dr</last_name>
      <phone>18610772626</phone>
      <email>jingxuezh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

